ÂÜÀòÂÒÂ×

Mardi Dier currently serves as Chief Financial Officer at Madrigal Pharmaceuticals since February 2024 and is a member of the Board of Advisors at UCLA Anderson School of Management since May 2022. Dier holds board member positions at Synthekine, Prelude Therapeutics Incorporated, and ORIC Pharmaceuticals, all active since 2021 and 2020, respectively. Previously, Dier was Chief Financial Officer and Chief Business Officer at ACELYRIN, INC. until August 2023 and served as Chief Financial Officer at Ultragenyx Pharmaceutical Inc. from October 2020 to November 2022. Dier's extensive experience also includes a board member role at Adamas Pharmaceuticals, Inc. and a long tenure at Portola Pharmaceuticals, where the role included EVP, CFO, and Head of Business Development before its acquisition by Alexion in July 2020. Prior to this, Dier was VP of Investor Relations at Chiron Corporation in 2003. Mardi Dier holds an MBA from UCLA Anderson School of Management and a Bachelor of Science in Biology from Stanford University.